Since it is widely acknowledged that tumor microenvironment acidification gains special importance for both drug availability and tumor–host immune interactions, the authors concluded that it was CA IX inhibitory activity of AZ that intensified the tumor-reductive effect of the conventional CHOP treatment and allowed for a prominent immune T-cell infiltration of tumors in vivo. This evidence concerns the gene CA9 and neoplasm.